Sequel Therapeutics

Sequel Therapeutics is a San Diego-based biotechnology company focused on developing next-generation, off-the-shelf cell therapies for cancer. The company leverages a proprietary induced pluripotent stem cell (iPSC) platform to create standardized and scalable natural killer (NK) cell therapies. Founded by industry veterans from Juno Therapeutics and Lyell Immunopharma, Sequel aims to overcome the limitations of current autologous treatments by engineering cells for improved potency and persistence. Their approach targets both hematologic malignancies and solid tumors through advanced genetic engineering. The company is backed by top-tier life science investors and operates with a mission to make curative cellular medicines broadly accessible to patients.